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Abstract
Objective To examine a reported association between use of angiotensin
converting enzyme (ACE) inhibitors during the first trimester and risk of
malformations in offspring.
Design A population based, retrospective cohort study linking automated
clinical and pharmacy databases including comprehensive electronic
medical records.
Participants Pregnant women and their live born offspring (465 754
mother-infant pairs) in the Kaiser Permanente Northern California region
from 1995 to 2008.
Main outcome measure Congenital malformation in live births.
Results The prevalence of ACE inhibitor use in the first trimester only
was 0.9/1000, and the use of other antihypertensive medications was
2.4/1000. After adjustment for maternal age, ethnicity, parity, and obesity,
use of ACE inhibitors during the first trimester only seemed to be
associated with increased risk of congenital heart defects in offspring
compared with normal controls (those with neither hypertension nor use
of any antihypertensives during pregnancy) (15/381 (3.9%) v
6232/400 021 (1.6%) cases, odds ratio 1.54 (95% confidence interval
0.90 to 2.62)). A similar association was observed for use of other
antihypertensives (28/1090 (2.6%) cases of congenital heart defects,
odds ratio 1.52 (1.04 to 2.21)). However, compared with hypertension
controls (those with a diagnosis of hypertension but without use of
antihypertensives) (708/29 735 (2.4%) cases of congenital heart defects),
neither use of ACE inhibitors or of other antihypertensives in the first
trimester was associated with increased congenital heart defects risk
(odds ratios 1.14 (0.65 to 1.98) and1.12 (0.76 to 1.64) respectively).
Conclusions Maternal use of ACE inhibitors in the first trimester has a
risk profile similar to the use of other antihypertensives regarding
malformations in live born offspring. The apparent increased risk of
malformations associated with use of ACE inhibitors (and other
antihypertensives) in the first trimester is likely due to the underlying
hypertension rather than the medications.
Introduction
Angiotensin converting enzyme (ACE) inhibitors are a class of
antihypertensive drug and are among themost widely prescribed
drugs for hypertension. Their fetal toxicity in the second or third
trimesters has been well documented,1 2 but, until recently, their
teratogenic effect in the first trimester was largely unknown.3 4
A study based on data from the TennesseeMedicaid population
reported an increased risk of congenital anomalies associated
with use of ACE inhibitors during the first trimester, raising the
possibility of a teratogenic effect.4 5 This association seemed
unique to ACE inhibitors because there was no such association
with use of other antihypertensives in the same study.5However,
two subsequent studies did not find the same pattern of
association with only ACE inhibitor use: both reported an
increased risk associated with use of ACE inhibitors during the
first trimester, but use of other types of antihypertensive also
showed an increased risk.6 7 These findings fail to confirm a
specific effect with ACE inhibitors and raise the question of
whether the observed risk associated with antihypertensives in
general was due to the effect of the drugs or the underlying
hypertension.
To examine the potential association between maternal use of
ACE inhibitors during the first trimester and the risk of
malformations in offspring, especially congenital heart defects
and neural tube defects, we conducted a large, population based,
cohort study based on information from more than 465 000
mother-infant pairs from 1995 to 2008 in the Kaiser Permanente
Correspondence to: D-K Li de-kun.li@kp.org
Appendix: Other antihypertensive drugs used in study (as supplied by the author) (see http://www.bmj.com/content/343/bmj.d5931/suppl/DC1)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5931 doi: 10.1136/bmj.d5931 Page 1 of 10
Research
RESEARCH
Northern California system. Our aim was to clarify whether the
observed risk was unique to ACE inhibitor use, to
antihypertensives in general, or to the underlying hypertension.
Methods
A population based, retrospective, cohort study was conducted
among the Kaiser Permanente Northern California member
population of women who delivered a live birth from 1995 to
2008. The study was approved by the Kaiser Permanente
Northern California Institutional Review Board. Kaiser
Permanente Northern California has well established automated
clinical and pharmacy databases that capture delivery, diagnosis
of malformation, dispenses of prescription drugs, and presence
of hypertension during pregnancy. In addition, through linkage
to various databases including California birth certificate data
and the Kaiser Permanente Northern California
Alpha-Fetoprotein Prenatal Screening Program, we were able
to obtain additional variables (such as maternal pre-existing
diabetes, pregnancy weight, age, ethnicity, education) for
adjustment as potential confounders. To examine the risk of
malformation in offspring, we included all live births in the
study population.
Ascertainment of maternal exposure to ACE
inhibitors and other antihypertensives during
pregnancy
The Pharmacy Information Management System is a
computerised pharmacy prescription and dispensation database
in Kaiser Permanente Northern California. This captures all
prescription drugs dispensed, with information on date
dispensed, dose, and days of supply. Use of ACE inhibitors and
other antihypertensives during pregnancy was ascertained
through linkage of the information from the database to women
who delivered live births from 1 January 1995 to 31 December
2008 identified from the Kaiser Permanente Northern California
clinical databases.
Last menstrual period was determined based on gestational age
recorded in the Kaiser Permanente Northern California clinical
databases in combination with the calendar date at delivery (last
menstrual period=date at delivery−gestational age). Through
linkage to information on dates of drug dispensation and days
of supply from the pharmacy database, we were able to identify
women who were exposed to ACE inhibitors and other
antihypertensives during pregnancy. We classified the timing
of exposure as: (a) use during the first trimester only, (b) use
during the second or third trimester only, and (c) use at any time
during pregnancy. Two cohorts of women who were exposed
to antihypertensive drugs during pregnancy were established:
a cohort exposed to ACE inhibitors and a cohort exposed to
antihypertensives other than ACE inhibitors. Any pregnant
women who used ACE inhibitors in isolation or in combination
with other drugs were classified into the cohort exposed to ACE
inhibitors. We excluded a few users of angiotensin receptor
blockers in this cohort since they have some pharmacological
similarities with ACE inhibitors. Users of all other
antihypertensive drugs (see appendix on bmj.com for the list)
were classified into the cohort of “other antihypertensive drug
users.”
Comparison cohorts
One of the most difficult methodological challenges in
pharmacoepidemiological studies is to control for the underlying
indication for the drugs being studied. Therefore, establishing
a comparable control group is crucial. Since the underlying
condition for ACE inhibitors is hypertension, we identified
pregnant women who had a diagnosis of hypertension at any
time from one year before their last menstrual period to the end
of their pregnancy but who were not prescribed any
antihypertensive drugs (based on our pharmacy data). This group
served as a control for the underlying indication of
antihypertensive drugs (that is, hypertension controls). The
remaining pregnant women who had neither a diagnosis of
hypertension nor use of any antihypertensive drug formed the
normal control group.
Ascertainment of malformations
All live born infants in the identified eligible mother-infant pairs
were linked to clinical databases (both inpatient and outpatient
data) including electronic medical records to identify diagnoses
of major malformations (ICD-9 CM (international classification
of diseases, ninth revision) codes 740.0–759.9). In order to allow
comparisons, we included malformations of similar types to
those included in the study by Cooper et al that reported the
association between ACE inhibitor use in the first trimester and
malformation risk in offspring.5
All infants were followed to the end of the study period, 31
December 2008, to maximise the use of existing clinical
information for a more complete ascertainment of
malformations. However, most malformations (for example,
89% of congenital heart defects identified) were diagnosed in
the infants before 1 year of age.
While the Kaiser Permanente Northern California automated
databases have been shown to be comprehensive and accurate,8 9
we conducted a validation study of the diagnoses of
malformations by comparing the diagnoses between medical
charts and our clinical databases. We randomly selected 237
maternal-infant pairs for a validation study. The diagnoses of
malformations were compared between the two data sources.
While medical records may not necessarily be error-free, the
diagnoses of malformations from our clinical databases and
medical records were quite consistent. Compared with medical
records, the sensitivity and specificity for diagnoses of
malformations recorded in the Kaiser Permanente Northern
California clinical databases were 100% and 94% respectively
for any malformations, and 98% and 99% respectively for
diagnoses of congenital heart defects.
Ascertainment of potential confounders and
effect modifiers
In addition to the underlying indications for use of
antihypertensive drugs, pre-existing diabetes before the index
pregnancy and being overweight during pregnancy were
probably the twomost important potential confounders or effect
modifiers. Women in the study cohorts with a pre-existing
diagnosis of diabetes were identified through linkage to the
Kaiser Permanente Northern California diabetes registry. Kaiser
Permanente Northern California has a well established diabetes
registry with over 200 000 members that ascertains, verifies,
and follows up all Kaiser Permanente Northern California
members with a diagnosis of diabetes (type 1, type 2, or previous
gestational diabetes). The registry has been estimated to be 98%
sensitive for diagnosed diabetes (compared with self reports
derived from a survey in 2000).10 This registry allowed us to
identify accurately women with a diagnosis of pre-existing
diabetes and provided an opportunity to examine the potential
interaction between use of ACE inhibitors during pregnancy
and pre-existing diabetes.
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In the current study population, about 70% of pregnant women
had information on body weight during the second trimester
(around 16–20 weeks of gestation) when they took part in
prenatal screening. Information on height was not available for
most subjects, however, so body mass index could not be
calculated. We used the 90th centile of body weight in the
second trimester (207 pounds (94 kg)) in our study population
as the cut-off point for overweight.
From the Kaiser Permanente Northern California databases, we
also had information on maternal age, ethnicity, and parity for
the pregnant women included. Through linkage to the California
State birth certificate data, we were able to obtain information
on some additional potential confounders including maternal
education levels and smoking during pregnancy. However,
because the California State birth certificate data were available
only up to 2006, we had missing data for those two potential
confounders for the births in 2007–8.
Analyses
We used logistic regression to control for confounders (maternal
age, ethnicity, parity, pre-existing diabetes, and overweight)
while examining the effect of maternal exposure to ACE
inhibitors and other antihypertensive drugs during pregnancy
on the risk of malformations in offspring. Because the rate of
malformation is relatively low, odds ratios and associated 95%
confidence intervals were used as approximation for relative
risk to measure the strength of the association and stability of
the estimates.
In addition to establishing a “hypertension only” cohort to
control for the underlying indication for antihypertensive drugs,
we extensively examined two important potential confounders,
pre-existing diabetes and overweight. Both were adjusted for
in the analyses and stratified for examination of potential
modifying effect. Other potential confounders including
maternal age, ethnicity, and parity were also controlled for
throughout the analyses. Finally, for some variables that were
available only from the California State birth certificate data
(thus, available only for births up to 2006), we conducted
separate analyses adjusting for those few variables among a
subset of the study population including births up to 2006.
Results
Overall, the study included 465 754 mother-infant pairs. The
prevalence of ACE inhibitor use during pregnancy was 1.6/1000
pregnancies, and use of other antihypertensive drugs was
38/1000. The prevalence of ACE inhibitor use in the first
trimester only was 0.9/1000 and in the second or third trimester
only was 0.1/1000. The prevalence of use of other
antihypertensive drugs in the corresponding periods was
2.4/1000 and 26.5/1000 respectively.
Table 1⇓ presents the characteristics of the four comparison
cohorts. Compared with both normal controls and hypertension
controls, women who used ACE inhibitors during pregnancy
were noticeably older and more likely to be African-American,
overweight (≥207 pounds (94 kg)), have pre-existing diabetes,
and have more live born children. On the other hand, the
characteristics of those who used other antihypertensive drugs
were similar to those of the normal controls and hypertension
controls except that they were slightly more overweight than
the normal controls but similar in weight to the hypertension
controls.
Maternal exposure to antihypertensive drugs
and risk of major malformations in offspring
Table 2⇓ presents results of the association between maternal
exposure to antihypertensive drugs, especially ACE inhibitors,
during various periods of pregnancy and the risk of major
malformations in offspring after adjustment for maternal age,
ethnicity, parity, pre-existing diabetes, and overweight. For
maternal exposure during the first trimester only, use of ACE
inhibitors was associated with about 20% increased risk of any
malformations in offspring compared with normal controls
(34/400 (8.5%) v 22 429/416 218 (5.4%) cases), though this
was not statistically significant. However, this association was
not unique to use of ACE inhibitors. Use of other
antihypertensive drugs showed a similar association (79/1141
(6.9%) cases of birth defects, 22% increased risk). Presence of
hypertension during pregnancy was also associated with a
similarly increased risk of malformations in offspring (2247/31
274 (7.2%) cases, odds ratio 1.25 (95% confidence interval 1.19
to 1.31)) (table 2⇓). Compared with the hypertension controls,
there was no increased risk of malformation associated with use
of either ACE inhibitors or other antihypertensive drugs.
Analyses for use of antihypertensives during the first trimester,
regardless of use in other trimesters, showed a largely similar
pattern of association (58/704 (8.2%) for ACE inhibitors,
327/4390 (7.5%) for other antihypertensives).
Maternal exposure to antihypertensive drugs
and risk of congenital heart and neural tube
defects in offspring
The association with congenital heart defects (ICD-9 codes
745–747) and neural tube defects (ICD-9 codes 740–742) was
further examined because these two types of malformations
were reported specifically as being associated with ACE
inhibitor use during the first trimester.5 The association between
use of antihypertensive drugs (ACE inhibitor or otherwise)
during the first trimester only and the risk of congenital heart
defects in offspring showed a similar pattern of the association.
Although maternal exposure to ACE inhibitors during the first
trimester only was potentially associated with a 54% increased
risk of congenital heart defects in offspring compared with
normal controls (15/381 (3.9%) v 6232/400 021 (1.6%) cases,
odds ratio 1.54 (0.90 to 2.62)), use of other antihypertensive
drugs was also associated with a 52% increased risk of
congenital heart defects (28/1090 (2.6%) cases, odds ratio 1.52
(1.04 to 2.21)). Even the presence of hypertension itself during
pregnancy was associated with a 41% increased risk of
congenital heart defects (708/29 735 (2.4%) cases, odds ratio
1.41 (1.30 to 1.53)). Therefore, compared with the hypertension
controls, use of antihypertensive drugs in pregnancy was not
associated with increased risk for congenital heart defects.
For neural tube defects, maternal use of either ACE inhibitors
or other antihypertensives was not associated with increased
risk, whereas the presence of hypertension during pregnancy
itself was associated with an increased risk of neural tube defects
(table 2⇓). The results among those who used ACE inhibitors
in the first trimester regardless of use during other trimesters
showed a similar pattern of the association.
Use of antihypertensive drugs during the
second or third trimesters
AlthoughACE inhibitor use during the second or third trimesters
only showed a similar pattern of association with any
malformations, congenital heart defects, or neural tube defects
as that shown by use of ACE inhibitors and other
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antihypertensives during the first trimester (table 2⇓), it was
also associated with a noticeably higher risk of malformations.
This increased fetal risk associated with ACE inhibitor use
during the second or third trimester is well documented, resulting
in ACE inhibitor use being classified by the US Food and Drug
Administration as a category D drug (generally not
recommended for use during the second or third trimester).
Influence of pre-existing diabetes and
overweight
Although pre-existing diabetes and obesity were adjusted for
in the analyses above, we further controlled for these factors by
excluding mothers with these two conditions. Firstly, we
repeated the analyses described in table 2 among those without
pre-existing diabetes. After adjustment for confounders, the
results in table 3⇓ show that the pattern of the observed
association betweenmaternal exposure to antihypertensive drugs
and the risk of malformations was largely similar to that
observed in the entire study population (table 2⇓). The similarity
existed for antihypertensive use during the first trimester as well
as during other periods of pregnancy, although the association
between ACE inhibitor use in the first trimester only and the
risk of any malformations no longer existed in this group (tables
3⇓).
Secondly, we conducted similar analyses among women not
overweight. We used the 90th centile of body weight (207
pounds, 94 kg) during the second trimester (the only available
information on body weight) as the cut-off value. We observed
a similar pattern of the associations as described above in
relation to pre-existing diabetes, although most associations
related to ACE inhibitor use in the first trimester only were not
statistically significant because of the small sample sizes in each
stratum (<90th centile, ≥90th centile, and unknown) (data not
shown).
Use of antihypertensive drugs without
underlying hypertension
Because some antihypertensive drugs can be used for conditions
other than hypertension, we further split the users of
antihypertensive drugs into two categories—with and without
a diagnosis of hypertension. To reduce the influence of
pre-existing diabetes, we conducted the analysis among those
without pre-existing diabetes. Overall, the pattern of the
association remained the same: use of both ACE inhibitors and
of other antihypertensives as well as hypertension itself
increased the risk of malformations (table 4⇓). The association
was not uniquely related to ACE inhibitor use. In addition, there
was no increased risk associated with use of antihypertensive
drugs (ACE inhibitors or otherwise) comparedwith hypertension
controls. Because of the reduced sample size from refinement
in individual categories, many estimates were not statistically
significant or could not be obtained.
Additional analyses
To examine whether there were other potential confounders in
addition to those adjusted for in the models, we conducted
further analyses after adjustment for maternal education level,
smoking status, and complications during pregnancy in a subset
of births up to 2006 for which information on those variables
was available from the California State birth certificate data.
The additional adjustment for those variables did not change
the observed associations (data not shown).
We also conducted additional analyses to examine any potential
dose-response relation. No such relation was observed with the
duration of use of either ACE inhibitors or other
antihypertensive drugs. In addition, restricting malformations
to those diagnosed before the age of 1 year did not change the
results.
Discussion
Comparison with previous studies
ACE inhibitor use during the second or third trimesters of
pregnancy is known to be associated with fetal toxicity. The
US Food and Drug Administration classifies ACE inhibitor use
during second and third trimesters as a category D drug (known
fetal risk). The potential teratogenic effect of ACE inhibitors
during the first trimester was raised in a report of increased risk
of malformations after maternal exposure to ACE inhibitors in
the first trimester in the Tennessee Medicaid population.5 This
observed association was specifically related to ACE inhibitor
use and was not present for use of other antihypertensive drugs
in the study.5
Our study was based on a much larger and more ethnically
diverse population with well established clinical, pharmacy,
and registry databases. Although we observed an increased risk
of malformations associated with ACE inhibitor use in the first
trimester compared with normal controls, this association was
not unique to ACE inhibitors. Use of other antihypertensive
drugs in the first trimester showed a similarly increased risk of
malformations in both the overall population and in those
women without pre-existing diabetes. Therefore, our results do
not support the argument that maternal use of ACE inhibitors
in the first trimester significantly increases the risk of fetal
malformations more than any other antihypertensive drug. Our
findings are consistent with those from two other studies which
showed that use of ACE inhibitors and of other antihypertensives
were associated with similarly increased risk of malformations.6 7
In addition, we observed that an underlying diagnosis of
hypertension was also associated with an increased risk of
malformations in offspring (tables 2⇓ and 3⇓). This raises the
question whether it was the underlying hypertension or the use
of antihypertensives that led to the increased risks of
malformation in offspring. Compared with the hypertension
controls in our study, use of antihypertensives (including ACE
inhibitors) in the first trimester showed no association with
increased risk of malformations. Most estimates of odds ratio
were around 1. For example, the risks of congenital heart defects
associated with maternal use of ACE inhibitors and of other
antihypertensives in the first trimester only were 1.14 (0.65 to
1.98) and 1.12 (0.76 to 1.64) respectively (table 2⇓).
Although our study did not confirm the reported unique
association between maternal use of ACE inhibitors in the first
trimester and increased risk of malformations,5 we did observe
a stronger association between maternal exposure to ACE
inhibitors during the second or third trimesters and the risk of
malformations than exposure to other antihypertensive drugs.
This fetal risk associated with maternal use of ACE inhibitors
during the later part of pregnancy is well known. Our
confirmation of this established association in the present study
provides support for our findings of the association with ACE
inhibitor use in the first trimester.
Many reasons might account for the different findings in our
study and those of Cooper et al.5 Firstly, the study populations
were quite different. Our study population was more than 15
times larger than that in the study of Cooper et al.5 In addition,
our study cohorts (ACE inhibitor users, users of other
antihypertensives, hypertension controls, and normal controls)
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came from the same pool of members of Kaiser Permanente
Northern California, ensuring comparability among them. The
earlier study population was based on the Tennessee Medicaid
population,5whereas ours represented the underlying population
in the service areas of the Northern California region with a
different the ethnic composition—about 48%African-Americans
in the earlier study compared with 10% in our study.
Strengths of the study
By identifying and establishing a cohort of pregnant women
who had hypertension but did not use antihypertensive drugs,
we were able to examine and disentangle the pharmacological
effect of antihypertensive drugs from the effect of underlying
hypertension. Our results show that the underlying hypertension
is more likely to be associated with increased risk of
malformations in offspring than antihypertensive drug use in
the first trimester. While hypertension in pregnancy has been
associated with some adverse pregnancy outcomes, including
preterm delivery and fetal growth retardation, its relation with
the risk of birth defects is unclear.11 In addition, we were able
to separate users of antihypertensive drugs into two groups:
those with a diagnosis of hypertension and those without the
diagnosis. These separate cohorts allowed further
disentanglement of the effect of drugs from underlying
indications for the drugs.
Another strength of our study is our detailed analyses of
antihypertensive drug exposure in various periods during
pregnancy (in the first trimester only, any exposure in the first
trimester, and exposure in the second or third trimesters only).
Such analyses allowed us to confirm the presence of the known
fetal toxicity due to ACE inhibitor use during the second or
third trimester, providing confidence in our overall findings.
However, the small number of womenwho used ACE inhibitors
in the second or third trimester made the estimates relatively
unstable.
Limitations of the study
As with any pharmacoepidemiological study using automated
databases, assumptions had to be made. Although dispensary
information from the Kaiser Permanente Northern California
pharmacy data was accurate, women’s compliance in taking the
prescribed drugs is unknown. Given that antihypertensive drugs
are for serious underlying conditions, compliance was expected
to be high. Any non-compliance should be similar between ACE
inhibitor users and users of other antihypertensive drugs, thus
not affecting the observation that use of ACE inhibitors and of
other antihypertensives in the first trimester had similar risk
profiles in relation to malformations in offspring.
Another potential limitation of our reliance on pharmacy
databases is the inability to identify women who obtained
prescriptions from pharmacies outside Kaiser Permanente
Northern California. However, members of Kaiser Permanente
Northern California had substantial incentives to obtain drugs
fromKaiser Permanente Northern California’s own pharmacies
in terms of the benefit of drug coverage with low co-payment.
In addition, given the ACE inhibitor use in the first trimester
only was rare among the pregnant women (0.9/1000), any
potential impact from women who were misclassified as
non-users (because of their obtaining ACE inhibitors from
outside pharmacies) would be negligible because the percentage
would be so small.
Also, we had little information on the characteristics of women
with treated and untreated hypertension. Therefore, we were
not able to distinguish between the potential underlying
differences in the risk of having a child with birth defects and
treatment effect on the risk of birth defects. Nevertheless,
untreated hypertension is likely to be less severe than treated
hypertension, and the risk of having a child with birth defects
was quite similar between women with treated hypertension (in
the first trimester) and those with untreated hypertension.
Finally, our study could not rule out the possibility that ACE
inhibitor use during pregnancy might be associated with the
risk of some subtle defects that we were not able to examine.
Conclusions
In this large, population based, cohort study we observed a
similar elevated risk of malformations in offspring among
women who, during the first trimester of pregnancy, had used
either ACE inhibitors or other antihypertensive drugs or who
had hypertension and did not use antihypertensives. Our finding
did not confirm a previously reported unique association
between use of ACE inhibitors in the first trimester and risk of
malformations in offspring. Our finding suggests that it is likely
the underlying hypertension, rather than use of antihypertensive
drugs in the first trimester, that increases the risk of
malformations in offspring.
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Tables
Table 1| Distribution of characteristics by use of antihypertensive medications during pregnancy among 465 754 women who delivered
live offspring in the Kaiser Permanente Northern California region during 1995–2008. Values are numbers (percentages) of subjects
ACE inhibitor use (n=755)§
Other antihypertensive use
(n=17 507)‡
Hypertension controls
(n=31 274)†Normal controls (n=416 218)*Maternal characteristics
Age at delivery (years):
7 (0.9)899 (5.1)2019 (6.5)27 839 (6.7)<20
44 (5.8)2340 (13.4)5210 (16.7)73 186 (17.6)20–<25
102 (13.5)4289 (24.5)8124 (26.0)119 109 (28.6)25–<30
210 (27.8)5113 (29.2)8648 (27.7)118 237 (28.4)30–<35
253 (33.5)3647 (20.8)5554 (17.8)62 812 (15.1)35–<40
138 (18.3)1204 (6.9)1710 (5.5)14 523 (3.5)≥40
1 (0.1)15 (0.1)9 (0.03)512 (0.1)Unknown
Ethnicity:
264 (35.0)8139 (46.5)15 286 (48.9)185 778 (44.6)White
150 (19.9)2473 (14.1)3471 (11.1)34 988 (8.4)African American
130 (17.2)2833 (16.2)6179 (19.8)89 377 (21.5)Hispanic
159 (21.1)3286 (18.8)5143 (16.4)84 594 (20.3)Asian
8 (1.1)195 (1.1)313 (1.0)3477 (0.8)Other
44 (5.8)581 (3.3)882 (2.8)18 004 (4.3)Unknown
Parity (prior live births):
202 (26.8)6319 (36.1)15 642 (50.0)161 182 (38.7)0
191 (25.3)5373 (30.7)8560 (27.4)135 153 (32.5)1
167 (22.1)3046 (17.4)3842 (12.3)65 195 (15.7)2
134 (17.8)1952 (11.2)2227 (7.1)35 375 (8.5)≥3
61 (8.1)817 (4.7)1003 (3.2)19 313 (4.6)Unknown
Overweight or obesity¶:
326 (43.2)10 220 (58.4)17 377 (55.6)263 013 (63.2)No
212 (28.1)2229 (12.7)5736 (18.3)25 723 (6.2)Yes
217 (28.7)5058 (28.9)8161 (26.1)127 482 (30.6)Unknown
Pre-existing diabetes:
289 (38.3)470 (2.7)689 (2.2)1651 (0.4)Yes
466 (61.7)17 037 (97.3)30 585 (97.8)414 567 (99.6)No
*No use of antihypertensives during pregnancy and no diagnosis of hypertension.
†No use of antihypertensives during pregnancy but with a diagnosis of hypertension.
‡Use of antihypertensives other than ACE inhibitors during pregnancy.
§Use of ACE inhibitors during pregnancy.
¶90th centile of body weight in the second trimester (207 pounds, 94 kg) used as cut-off point for overweight or obesity.
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Table 2| Risk of major birth defects in offspring of 465 754 women who delivered in the Kaiser Permanente Northern California region
during 1995–2008 by maternal use of antihypertensive medications during pregnancy
Odds ratio (95% CI)
No (%) of mother-infant
pairs Adjusted*Crude
Any birth defect
—ReferenceReference22 429/416 218 (5.4)Normal controls†
Reference1.25 (1.19 to 1.31)1.36 (1.30 to 1.42)2247/31 274 (7.2)Hypertension controls‡
Antihypertensive use:
Only in 1st trimester:
1.00 (0.79 to 1.27)1.22 (0.97 to 1.54)1.31 (1.04 to 1.64)79/1141 (6.9)Other antihypertensives§
0.97 (0.67 to 1.41)1.20 (0.84 to 1.72)1.63 (1.15 to 2.32)34/400 (8.5)ACE inhibitors¶
Any in 1st trimester**
1.07 (0.94 to 1.21)1.29 (1.15 to 1.45)1.41 (1.26 to 1.58)327/4390 (7.5)Other antihypertensives§
0.97 (0.73 to 1.30)1.15 (0.87 to 1.52)1.58 (1.21 to 2.06)58/704 (8.2)ACE inhibitors¶
Only in 2nd or 3rd trimesters:
1.53 (1.43 to 1.65)1.94 (1.83 to 2.05)1.99 (1.88 to 2.11)1334/13 117 (10.2)Other antihypertensives§
1.88 (0.84 to 4.20)2.34 (1.05 to 5.22)2.80 (1.26 to 6.21)7/51 (13.7)ACE inhibitors¶
Congenital heart defects††
—ReferenceReference6232/400 021 (1.6)Normal controls†
Reference1.41 (1.30 to 1.53)1.54 (1.43 to 1.67)708/29 735 (2.4)Hypertension controls‡
Antihypertensive use:
Only in 1st trimester:
1.12 (0.76 to 1.64)1.52 (1.04 to 2.21)1.67 (1.14 to 2.43)28/1090 (2.6)Other antihypertensives§
1.14 (0.65 to 1.98)1.54 (0.90 to 2.62)2.59 (1.54 to 4.34)15/381 (3.9)ACE inhibitors¶
Any in 1st trimester**
1.24 (1.02 to 1.52)1.67 (1.39 to 2.01)1.91 (1.59 to 2.29)123/4186 (2.9)Other antihypertensives§
1.10 (0.70 to 1.71)1.39 (0.91 to 2.13)2.35 (1.57 to 3.54)24/670 (3.6)ACE inhibitors¶
Only in 2nd or 3rd trimesters:
2.02 (1.81 to 2.27)2.90 (2.65 to 3.16)3.04 (2.78 to 3.32)566/12 349 (4.6)Other antihypertensives§
3.04 (1.08 to 8.56)4.28 (1.53 to 11.97)5.75 (2.06 to 15.99)4/48 (8.3)ACE inhibitors¶
Neural tube defects††
—ReferenceReference2447/396 236 (0.6)Normal controls†
Reference1.43 (1.26 to 1.62)1.56 (1.38 to 1.76)281/29 308 (1.0)Hypertension controls‡
Antihypertensive use:
Only in 1st trimester:
0.90 (0.46 to 1.76)1.26 (0.65 to 2.44)1.36 (0.71 to 2.63)9/1071 (0.8)Other antihypertensives§
0.44 (0.11 to 1.84)0.59 (0.14 to 2.38)0.88 (0.22 to 3.53)2/368 (0.5)ACE inhibitors¶
Any in 1st trimester**
1.07 (0.76 to 1.50)1.46 (1.07 to 2.00)1.62 (1.19 to 2.22)41/4104 (1.0)Other antihypertensives§
0.86 (0.37 to 2.03)1.03 (0.45 to 2.36)1.50 (0.67 to 3.34)6/652 (0.9)ACE inhibitors¶
Only in 2nd or 3rd trimesters:
1.71 (1.41 to 2.06)2.51 (2.16 to 2.91)2.64 (2.27 to 3.06)193/11 976 (1.6)Other antihypertensives§
3.79 (0.90 to 15.87)5.39 (1.30 to 22.40)7.33 (1.78 to 30.21)2/46 (4.3)ACE inhibitors¶
*Adjusted for pre-existing diabetes, maternal age, ethnicity, parity, and maternal weight, and with different reference categories (normal controls or hypertension
controls).
†No use of antihypertensives during pregnancy and no diagnosis of hypertension.
‡No use of antihypertensives during pregnancy but with a diagnosis of hypertension.
§Use of antihypertensives other than ACE inhibitors during pregnancy.
¶Use of ACE inhibitors during pregnancy.
**Any use of antihypertensives in first trimester regardless of use in other trimesters.
††Excluding cases of other birth defects from the denominator.
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Table 3| Risk of major birth defects in offspring of 462 655 women without pre-existing diabetes who delivered in the Kaiser Permanente
Northern California region during 1995–2008 by maternal use of antihypertensive medications during pregnancy
Odds ratio (95% CI)
No (%) of mother-infant
pairs Adjusted*Crude
Any birth defect
—ReferenceReference22 277/414 567 (5.4)Normal controls†
Reference1.25 (1.19 to 1.31)1.34 (1.28 to 1.40)2162/30 585 (7.1)Hypertension controls‡
Antihypertensive use:
Only in 1st trimester:
0.98 (0.77 to 1.25)1.20 (0.94 to 1.52)1.26 (0.99 to 1.59)74/1111 (6.7)Other antihypertensives§
0.88 (0.52 to 1.50)1.07 (0.64 to 1.81)1.13 (0.67 to 1.91)15/248 (6.1)ACE inhibitors¶
Any in 1st trimester**
1.08 (0.95 to 1.23)1.31 (1.16 to 1.47)1.40 (1.24 to 1.57)308/4198 (7.3)Other antihypertensives§
0.89 (0.59 to 1.34)1.05 (0.70 to 1.57)1.10 (0.74 to 1.65)25/424 (5.9)ACE inhibitors¶
Only in 2nd or 3rd trimesters:
1.55 (1.44 to 1.67)1.95 (1.84 to 2.07)1.98 (1.87 to 2.10)1299/12 839 (10.1)Other antihypertensives§
2.22 (0.93 to 5.28)2.78 (1.17 to 6.61)2.94 (1.34 to 6.98)6/42 (14.3)ACE inhibitors¶
Congenital heart defects††
—ReferenceReference6170/398 460 (1.6)Normal controls†
Reference1.40 (1.29 to 1.52)1.49 (1.38 to 1.62)669/29 092 (2.3)Hypertension controls‡
Antihypertensive use:
Only in 1st trimester:
1.10 (0.74 to 1.64)1.50 (1.01 to 2.21)1.59 (1.08 to 2.35)26/1063 (2.5)Other antihypertensives§
1.47 (0.72 to 3.00)1.98 (0.98 to 4.02)2.19 (1.08 to 4.42)8/241 (3.3)ACE inhibitors¶
Any in 1st trimester**
1.29 (1.05 to 1.59)1.75 (1.45 to 2.11)1.89 (1.57 to 2.29)116/4006 (2.9)Other antihypertensives§
1.31 (0.73 to 2.35)1.73 (0.97 to 3.07)1.91 (1.08 to 3.40)12/411 (2.9)ACE inhibitors¶
Only in 2nd or 3rd trimesters:
2.08 (1.85 to 2.34)2.95 (2.70 to 3.23)3.03 (2.77 to 3.31)549/12 089 (4.5)Other antihypertensives§
4.43 (1.57 to 12.52)6.31 (2.24 to 17.76)7.06 (2.51 to 19.85)4/40 (10.0)ACE inhibitors¶
Neural tube defects††
—ReferenceReference2425/394 715 (0.6)Normal controls†
Reference1.43 (1.26 to 1.62)1.53 (1.34 to 1.73)268/28 691 (0.9)Hypertension controls‡
Antihypertensive use:
Only in 1st trimester:
0.94 (0.48 to 1.85)1.33 (0.69 to 2.57)1.40 (0.73 to 2.71)9/1046 (0.9)Other antihypertensives§
0.93 (0.23 to 3.80)1.29 (0.32 to 5.19)1.39 (0.35 to 5.59)2/235 (0.9)ACE inhibitors¶
Any in 1st trimester**
1.12 (0.80 to 1.58)1.55 (1.13 to 2.13)1.66 (1.22 to 2.28)40/3930 (1.0)Other antihypertensives§
1.65 (0.73 to 3.77)2.24 (1.00 to 5.04)2.44 (1.09 to 5.47)6/405 (1.5)ACE inhibitors¶
Only in 2nd or 3rd trimesters:
1.71 (1.41 to 2.07)2.52 (2.17 to 2.93)2.59 (2.23 to 3.02)185/11 725 (1.6)Other antihypertensives§
5.48 (1.31 to 22.99)7.88 (1.89 to 32.79)9.02 (2.18 to 37.40)2/38 (5.3)ACE inhibitors¶
*Adjusted for pre-existing diabetes, maternal age, ethnicity, parity, and maternal weight, and with different reference categories (normal controls or hypertension
controls).
†No use of antihypertensives during pregnancy and no diagnosis of hypertension.
‡No use of antihypertensives during pregnancy but with a diagnosis of hypertension.
§Use of antihypertensives other than ACE inhibitors during pregnancy.
¶Use of ACE inhibitors during pregnancy.
**Any use of antihypertensives in first trimester regardless of use in other trimesters.
††Excluding cases of other birth defects from the denominator.
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Table 4| Risk of major birth defects in offspring of 462 655 women without pre-existing diabetes who delivered in the Kaiser Permanente
Northern California region during 1995–2008 by maternal use of antihypertensive medications during the first trimester of pregnancy and
an underlying diagnosis of hypertension
Odds ratio (95% CI)
No (%) of mother-infant
pairs Adjusted*Crude
Any birth defect
—ReferenceReference22 277/414 567 (5.4)Normal controls†
Reference1.25 (1.19 to 1.31)1.34 (1.28 to 1.40)2162/30 585 (7.1)Hypertension controls‡
Antihypertensive use:
Other antihypertensives§:
1.08 (0.81 to 1.43)1.32 (1.00 to 1.75)1.37 (1.04 to 1.82)53/733 (7.2)Without hypertension
0.81 (0.52 to 1.26)0.96 (0.62 to 1.50)1.04 (0.67 to 1.61)21/378 (5.6)With hypertension
ACE inhibitors¶:
NANANA0/22 (0)Without hypertension
0.97 (0.57 to 1.65)1.17 (0.69 to 1.98)1.25 (0.74 to 2.11)15/226 (6.6)With hypertension
Congenital heart defects**
—ReferenceReference6170/398 460 (1.6)Normal controls†
Reference1.40 (1.29 to 1.52)1.49 (1.38 to 1.62)669/29 092 (2.3)Hypertension controls‡
Antihypertensive use:
Other antihypertensives§:
1.12 (0.68 to 1.82)1.53 (0.95 to 2.48)1.59 (0.98 to 2.57)17/697 (2.4)Without hypertension
1.08 (0.55 to 2.11)1.43 (0.74 to 2.78)1.60 (0.83 to 3.11)9/366 (2.5)With hypertension
ACE inhibitors¶:
NANANA0/22 (0)Without hypertension
1.62 (0.79 to 3.31)2.16 (1.07 to 4.39)2.41 (1.19 to 4.89)8/219 (3.7)With hypertension
Neural tube defects**
—ReferenceReference2425/394 715 (0.6)Normal controls†
Reference1.43 (1.26 to 1.62)1.53 (1.34 to 1.73)268/28 691 (0.9)Hypertension controls‡
Antihypertensive use:
Other antihypertensives§:
0.81 (0.33 to 1.96)1.15 (0.48 to 2.77)1.19 (0.49 to 2.87)5/685 (0.7)Without hypertension
1.21 (0.44 to 3.27)1.66 (0.62 to 4.46)1.81 (0.68 to 4.86)4/361 (1.1)With hypertension
ACE inhibitors¶:
NANANA0/22 (0)Without hypertension
1.04 (0.25 to 4.22)1.41 (0.35 to 5.69)1.53 (0.38 to 6.18)2/213 (0.9)With hypertension
*Adjusted for pre-existing diabetes, maternal age, ethnicity, parity, and maternal weight, and with different reference categories (normal controls or hypertension
controls).
†No use of antihypertensives during pregnancy and no diagnosis of hypertension.
‡No use of antihypertensives during pregnancy but with a diagnosis of hypertension.
§Use of antihypertensives other than ACE inhibitors during pregnancy.
¶Use of ACE inhibitors during pregnancy.
**Excluding cases of other birth defects from the denominator.
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